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Abstract
BACKGROUND: Many data support that oxidative stress and inflammation represent a pathway to pathology in 
a number of depressed patients. Therefore, investigating this pathway presents an area for developing potential 
therapeutic strategies for depression.
AIM: This study compares the serum level of malondialdehyde (MDA), superoxide dismutase (SOD), and nuclear 
factor erythroid 2-related factor 2 (Nrf2) in depressed and non-depressed subjects and correlate between their levels 
with severity of disorder, socio-demographic characteristics, previous hospitalization, and number of episodes.
METHODS: A total of 60 patients diagnosed with major depressive disorder (MDD) from the Psychiatric Outpatient 
Clinic in Al-Zahra University Hospital, Cairo, Egypt, during the period from July 1, 2018, to December 31, 2018. A 
cross-matched control group of 60 subjects was selected from employers working in the hospital, complete psychiatric 
history, Hamilton Depression rating scale was done and serum levels of MDA, Nrf2, and SOD were estimated.
RESULTS: No statistical difference between patient and control group was observed regarding age, sex, education, 
and marital status. The number of patients with mild depression was 28 (46.7%), moderate depression 18 (30%), 
and severe depression 14 (23.3%). The mean duration of illness in years was 6.13, and mean number of episodes 
was 3.66. MDA level was significantly elevated in the patient group than the control one. Meanwhile, SOD and Nrf2 
were significantly lower in the patient group than the control. There was significant relationship between duration of 
illness and number of episodes and MDA, Nrf2, and SOD levels.
CONCLUSION: Our results indicate that oxidative stress can attribute to the occurrence of MDD.
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Introduction
Depression is a state of low mood and 
demotivation affecting individual’s feelings, cognition, 
and behaviors. It is the most common psychiatric disorder 
and is considered a high-risk factor of suicide [1].
Researchers suggest that depression does 
not stem from simply too much or too little brain 
chemicals. Many data support the hypothesis that 
inflammation represents a pathway to pathology in a 
number of depressed patients. Therefore, investigating 
this pathway presents an area for developing potential 
therapeutic strategies for depression [2].
According to the WHO; more than 300 
million people suffer from depression. The WHO 
identified strong relations between depression and 
other disorders. It increases the risk of substance use 
disorders, diabetes mellitus, and heart disease [3]. At 
worst, it leads to suicide which claims 800,000 of lives 
every year [4]. Depression induces global disability 
(7.5 of all years lived with disability in 2015). Major 
depression is projected to become the second leading 
cause of disability all over the world [3].
A growing body of evidence supports the 
relation between depression and inflammation [5]. 
Studies showed more cytokines production in 
medicated depressed or drug free patients than 
controls [6]. Oxidative stress plays a role in neuronal 
cell death directly or through an inflammatory process. 
There is an increasing evidence of excess level of 
reactive oxygen species (ROS) and inflammatory 
biomarkers in depressed patients with activation of 
stress kinases promoting further oxidative stress 
and neuroinflammation with subsequent cell death. 
Oxidative stress leads to oxidized lipids, proteins, and 
nucleic acids as result of greater ROS [7] targeting 
fatty acids, monoamines of the brain. Monoamine 
oxidation produces superoxide anions; therefore, a 
critical balance is required between free radicals and 
antioxidants mechanisms.
Oxidative stress damage is evidenced 
by an increased level of malondialdehyde (MDA), 
polyunsaturated fatty acid peroxidation by product [8]. In 
the same context, nuclear factor erythroid 2-related factor 
2 (Nrf2) is the master regulator of inducible antioxidant 
responses [9]. The activation of Nrf2 plays a key role in 
inflammation [10] through the reduction of ROS production 
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and the macrophage M1 phenotype [11], regulating 
antioxidant response element (ARE) gene expression 
The Keap1 (Kelch-like ECH-associated protein 1), and 
the recruitment of inflammatory cells. During oxidative 
stress, free Nrf2 translocates to the nucleus and binds 
to ARE genes such as hemeoxygenase-1 inhibiting 
the NF-KB pathway which leads to downregulation of 
pro-inflammatory cytokines [12]. In inflammatory disorders 
and neurodegenerative diseases, Nrf2 stimulator has 
become an important therapeutic strategy [13], [14], [15]. 
Hence, the discovery of new Nrf2 stimulator for clinical 
study is an essential target in drug discovery.
Nrf2 has a crucial role in inflammation which is 
implicated in depression. Its deletion in mice results in 
reduced dopamine and serotonin in prefrontal cortex [16]. 
Furthermore, in a chronic stress paradigm, Nrf2 has a 
mechanism responsible for antidepressant response [17]. 
A study by Martín-Hernández (2018) [18] was done on 
postmortem brains of depressed patients showed decreased 
expression of Nrf2 in the dorsolateral prefrontal cortex. 
Furthermore, superoxide dismutase (SOD) is an enzyme 
that converts superoxide anion radicals to molecular oxygen 
and hydrogen peroxide controlling ROS [19].
Aim
The aim of the study was to compare the 
serum levels of MDA, Nrf2, and SOD in depressed and 
non-depressed subjects and to correlate between their 
levels with the severity of disorder, socio-demographic 
characteristics, previous hospitalization, and number of 
episodes.
Participants
A convenience sample of 60 patients 
diagnosed with major depressive disorder (MDD) from 
the Psychiatric Outpatient Clinic in Al-Zahra Hospital, 
Cairo, Egypt. The diagnosis was based on the DSM 
5 criteria for MDD. A cross-matched control group 
comprised 60 subjects were selected from employers 
working in the hospital. All subjects provided written 
informed consent, approved applying personal data 
for research. The study was done consistent with good 
clinical practice and Declaration of Helsinki and the 
World Health Organization guidelines.
Inclusion criteria
The following criteria were included in the study:
1. Age range between 18 and 55.
2. Both sexes were included.
Exclusion criteria
The following criteria were excluded from the 
study:
1. Comorbid psychiatric disorders.
2. Medical illnesses such as endocrine, metabolic, 
neurological, or autoimmune disorders.
3. Infections, inflammatory reactions, or allergy 
within the past 2 weeks preceding blood 
sampling or antioxidant medication.
Measures
All subjects were subjected to the following:
1. Complete psychiatric sheet and examination 
and diagnosis were based on DSM 5 criteria 
for diagnosis of MDD.
2. Hamilton depression rating scale (HAMD) [20], 
its Arabic version [21]: A useful scale used to 
determine patients’ severity of depression.
3. Serum levels of MDA and SOD were estimated 
using Biodiagnostic kit, Egypt.
4. Serum Nrf2 levels was determined using 
Elabscience Biotechnology Co. Ltd. Enzyme-
linked immunosorbent assay (ELISA) kit.
Procedure
Blood samples were taken from both groups 
under sterile conditions. Serum levels of MDA and SOD 
were estimated according to the methods described 
by Misra and Fridovich [22] and Ohkawa et al. [23], 
respectively.
Serum Nrf2 levels was determined using 
Elabscience Biotechnology Co. Ltd. ELISA kit. We 
followed the manufacturer’s instructions for definition 
and calculating results. Standards and samples 
were pipetted into wells with immobilized antibodies 
specific for human Nrf2, and then were incubated. 
After incubation and washing, biotinylated antihuman 
Nrf2 antibody was added. Having washed away 
any unbound substances, biotinylated antibody and 
horseradish peroxidase-conjugated streptavidin were 
pipetted into the wells, which were washed once again. 
tetramethylbenzidine substrate solution was added to 
the wells; color developed proportionally to the amount 
of Nrf2 bound. Color development was discontinued 
(Stop Solution) and its intensity was measured using 
the Thermo Labsystems Multiskan Ascent 354 (Lab 
Recyclers) at 450 nm.
Statistical analysis
The Statistical Package for the Social 
Sciences (SPSS version 21.0) was used for data entry 
and analysis. Descriptive statistics were computed in 
the form of frequency and percentage for categorical 
data and in the form of measures of central tendency 
(arithmetic mean) and measures of dispersion (standard 
deviation) for continuous variables. Chi-square test 
was used to test for the association and/or difference 
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between categorical variables. Student’s t-test was 
used for comparing two means and ANOVA for 
comparing more than 2 means. Multiple comparisons 
among sample means were checked by post hoc LSD. 
Pearson’s correlation coefficient (r) or spearmen’s rank 
order correlation coefficient was used for testing the 
association between two variables. Differences were 
considered as statistically significant when p = 0.05.
Results
The socio-demographic data showed that 
cases were matching with the controls, no statistical 
difference between patient and control groups was 
observed regarding age, sex, education, and marital 
status (Table 1).
Table 1: Socio-demographic characteristics of both patients 
and control groups
Characteristics Patient 
group n=60
Control 
group n=60
Sig test p value
Age (years) (mean±SD) 41.03 ± 4.46 42.8 ± 4.28 t-test=2.2 df=118 >0.05
Gender
Males 18 22 χ2=0.6
df=1
>0.05
Females 42 38
Education
Primary 34 30 χ2=2
df=4
>0.05
Secondary 18 16
High 8 14
Marital status
Single 4 10 χ2=6.23
df=6
>0.05
Married 36 28
Divorced 14 10
Widowed 6 12
According to HAMD, the number of patients with 
mild depression was 28 (46.7%), moderate depression 
was 18 (30%), and severe depression was 14 (23.3%). 
The mean duration of illness in years was 6.13 and the 
mean number of episodes was 3.66 (Table 2).
Table 2: Severity of depression according to Hamilton 
depression rating scale and disease characteristics
Disease characteristics Patient group n=60
HDRS n (%)
Mild depression n (%) 28 (46.7)
Moderate depression n (%) 18 (30)
Severe depression n (%) 14 (23.3)
Duration of illness in years (Mean ± SD) 6.13 ± 2.4
Number of episodes(Mean ± SD) 3.66 ± 1.43
HDRS: Hamilton depression rating scale, SD: Standard deviation.
Comparison between patient and control 
groups regarding MDA, SOD, and Nrf2 showed that 
the MDA level was higher in the patient group than the 
control one with statistical significance; meanwhile, 
SOD and Nrf2 were significantly lower in the patient 
group than the control one (20.46 ± 2.55 pg/ml, 42.2 ± 
23.8 µ/ml, 0.4 ± 0.1 pg/ml vs. 12.74 ± 0.26 pg/ml, and 
131.02 ± 17.45 µ/ml, 1.02 ± 0.04 pg/ml, respectively) 
(Table 3).
Comparison between mild, moderate, severe 
depression, and control groups regarding MDA, SOD, 
and Nrf2 showed that patients with severe depression 
had significantly higher levels of MDA than those with 
mild depression; they also have significantly lower 
levels of SOD and Nrf2 than those with moderate 
depression and mild depression, respectively 
(Table 4).
Table 4: Comparison between mild, moderate, severe 
depression, and control groups regarding MDA, SOD, and Nrf2
Biomarkers Control group Mild 
depression
Moderate 
depression
Severe 
depression
p value
Malondialdehyde 12.74 ± 0.26 18.8 ± 2.95a 21.79 ± 0.43a 22.08 ± 
0.18a,b
<0.001
Superoxide 
dismutase
131.02 ± 17.45 56.03 ± 14.68a 46.99 ± 18.54a 8.4 ± 1.7a,b,c <0.001
Nrf2 1.02 ± 0.04 0.48 ± 0.091a 0.35 ± 0.06a 0.32 ± 0.05a,b,c <0.001
aSignificantly different from control, bSignificantly different from mild, cSignificantly different from moderate, 
post hoc LSD at p=0.05. MDA: Malondialdehyde, SOD: Superoxide dismutase, Nrf2: Nuclear factor 
erythroid 2-related factor 2.
Relationship between MDA, SOD, Nrf2, and 
other variables revealed that there was strong positive 
correlation between MDA, SOD, Nrf2 levels, and 
duration of illness in years and number of episodes and 
no correlation was found between MDA, SOD, Nrf2, 
and age and gender (Table 5).
Table 5: Relationship between MDA, SOD, Nrf2, and some 
variables (Age, gender, duration of illness, and number of 
episodes) in patient group
Variables Patients
R p value
Age and MDA 0.05 >0.05
Gender and MDA 0.21 >0.05
Duration of illness and MDA 0.76 <0.001
Number of episodes and MDA 0.81 <0.001
Age and SOD 0.23 >0.05
Gender and SOD 0.06 >0.05
Duration of illness and SOD 0.72 <0.001
Number of episodes and SOD 0.73 <0.001
Age and Nrf2 0.23 >0.05
Gender and Nrf2 0.11 >0.05
Duration of illness and Nrf2 0.78 <0.001
Number of episodes and Nrf2 0.84 <0.001
MDA: Malondialdehyde, SOD: Superoxide dismutase, Nrf2: Nuclear factor erythroid 2-related factor 2.
Discussion
Recent researches showed that major depression 
is associated with activation in immune-inflammatory 
markers and there is an evidence that this activation is 
related to overproduction of ROS [24]. Some studies 
reported an increase in catabolism (oxidation) of monoamine 
neurotransmitters in MDD. It was also hypothesized that 
alterations in some lipids lead to changes in serotonin and 
noradrenaline which is thought to be related to depression 
[25]. Moreover, an established relationship between lipid 
peroxidation and ROS is found [26].
In our study, we examined the levels of MDA, 
SOD, and Nrf2 in the sera of 60 depressed patients and 
60 controls and we found that MDA was significantly 
higher in patients than the control (20.46 ± 2.55 pg/ml 
Table 3: Comparison between patient and control groups 
regarding MDA, SOD, and Nrf2
Biomarkers Control group n=60 Patient group n=60 t-test p value
MDA 12.74 ± 0.26 20.46 ± 2.55 23.27 0.001
SOD 131.02 ± 17.45 42.2 ± 23.8 23.29 0.001
Nrf2 1.02 ± 0.04 0.4 ± 0.1 42.93 0.001
MDA: Malondialdehyde, SOD: Superoxide dismutase, Nrf2: Nuclear factor erythroid 2-related factor 2.
B - Clinical Sciences Psychiatry
504 https://www.id-press.eu/mjms/index
vs. 12.74 ± 0.26 pg/ml) and these results are consistent 
with those of Billici et al. [27] who included 30 depressed 
patients and 30 control and found that plasma MDA was 
significantly higher in depressed patients than control 
(4.82 ± 1.3 µmol/l vs. 2.89 ± 1.1). Moreover, they found 
a positive correlation with its plasma level and both the 
number of episodes and duration of illness (r = 0.28, 
p < 0.05).
Likewise, Bajpai et al. [28] examined the MDA 
level in 60 depressed patients and 40 controls and 
found that its level was significantly higher in patients 
than controls (1.95 ± 1.04 mmol/L vs. 0.366 ± 0.175).
Similarly, Camkurt et al. [29] found that 
MDA level was significantly higher in patients with 
major depression than controls with medians at 4.04 
nmol/mg and 1.64 nmol/mg, respectively. They also 
examined SOD which was significantly decreased 
in depressed patients than controls with means at 
143 µ/mg and 298.12/mg, respectively, p < 0.001 
and this matches with our study in which the SOD 
level was significantly less in patient group than the 
control one (42.2 ± 23.8 vs. 131.02 ± 17.45). Bajpai 
et al. [28] found that MDA was higher in patients than 
the controls (1.95 ± 1.04 mmol/l vs. 0.366 ± 0.175) 
and SOD was lower in patients (0.123 ± 0.068 µg/ml 
vs. 0.177 ± 0.042).
Likewise, several studies suggested elevated 
MDA levels in depression and a reduction following 
antidepressant therapy was documented by Mazereeuw 
et al. [30].
The present results suggest that oxidative 
stress, which is evidenced by elevated MDA marker 
levels, is disturbed in depressed patients.
Regarding Nrf2, in our study, we found that Nrf2 
was significantly decreased in depressed patients than 
controls. A recent study showed the reduced (−21%) 
expression of Nrf2 in the dorsolateral prefrontal cortex 
from MDD patients [18].
These results suggest that decreased Keap1-
Nrf2 signaling plays a key role in the pathophysiology of 
mood disorders such as MDD and bipolar disorder [31].
Only few studies have evaluated oxidative 
stress and the severity of depression.
In our study, patients with severe depression 
had significantly higher levels of MDA than those with 
mild depression. This was consistent with the study of 
Rangaswamy and Swath [32] who found that there was 
moderate positive correlation between MDA levels and 
clinical severity of depression as measured by 21-item 
Hamilton rating scale for depression score which was 
found to be statistically significant (r = 0.317, p = 0.025), 
and the study of Kotan et al. [33] who found that there 
was a positive correlation between the severity of 
depressive symptoms and SOD activity. This was in 
contrary to Bal et al. (2012) [34] who studied 42 patients 
(37 women, and 5 men) diagnosed with MDD and no 
correlation was found between HAMD scores and 
MDA at patient group. Furthermore, our study revealed 
significantly lower levels of SOD and Nrf2 in patients with 
moderate depression and mild depression, respectively, 
compared to control group. This was consistent with the 
study of Rawdin et al. [35] who found that Nrf 2 did differ 
along the continuum of depressive symptom severity 
across groups. Furthermore, Sarandol et al. [36] found 
a positive correlation between the severity of depressive 
symptoms and SOD activity exists.
Researchers have proposed that oxidative 
stress is one of the potential pathogenic mediators 
for depression because it easily affects neuronal cell 
functions of the brain and hence the relation is settled 
between oxidative stress and depressive symptom 
scores.
In the current study, there was a significant 
relationship between the duration of illness and number 
of episodes and both high levels of MDA and low levels 
of SOD and Nrf2 with strong positive correlation. This 
was consistent with the previous studies such as Billici 
et al. [27], Stefanescu and Ciobica (2012) [37].
This can be attributed to explanations proven 
by recent research which stated that inflammation 
and mitochondrial oxidative process which occur in 
depression generate free radicals excessively with 
subsequent increase in MDA, these species react with 
macromolecules of the cell such as polyunsaturated 
fatty acids, DNA, proteins, and hence, damaging 
them [28], [38]. Therefore, definitely, the more the 
duration of illness, the more the number of episodes, 
the more free radicals and tissue destruction with higher 
levels of MDA.
Hence, to enhance personalized treatment for 
depressed patients, accurate prediction and detection 
of factors contributing to severity and recurrence of 
episodes is mandatory.
Conclusion
Our results indicate that oxidative stress can 
affect MDD, as free radicals are generated together 
with antioxidant deficiency; this can attribute to the 
occurrence of MDD and gives us a better understanding 
of the pathophysiology of depression and hence 
developing new therapeutic strategies.
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